ORIC Reports Promising Efficacy & Safety Data From ORIC-944 Phase 1b Trial In MCRPC; Stock Up
29/5 03:46
(RTTNews) - ORIC Pharmaceuticals Inc. (ORIC) announced potentially best-in-class preliminary efficacy and safety data from the ongoing Phase 1b trial of once daily ORIC-944 in combination with androgen receptor (AR) inhibitors in patients with metastatic castration-resistant pros...